Image

Optimizing INtrinsic Capacity for Functional INdependence and to Impede FrailTY in Older Adults: Adaptation of the WHO-ICOPE for Healthy Ageing in Singapore

Optimizing INtrinsic Capacity for Functional INdependence and to Impede FrailTY in Older Adults: Adaptation of the WHO-ICOPE for Healthy Ageing in Singapore

Recruiting
60 years and older
All
Phase N/A

Powered by AI

Overview

The goal of this intervention study is to screen and identify frailty and decline in intrinsic capacity (physical and mental capacities) in community-dwelling older adults in Singapore, and to evaluate whether early identification and targeted interventions can improve health outcomes and support healthy ageing. The main questions it aims to answer are:

  • Can combined frailty and intrinsic capacity screening with targeted interventions prevent or reduce functional decline in older adults, as measured by changes in life space mobility?
  • Will at least 80% of screened older adults adhere to recommended care pathways and interventions?
  • Can this screening and intervention programme demonstrate sustainability through continued community participation and recruitment of new partner organizations beyond the initial implementation phase? The investigators will compare an intervention group (receiving immediate assessment and clinical referrals based on identified needs) to a wait-list control group (receiving the same interventions 12 months later) to see if early intervention leads to better health outcomes and quality of life.

Participants will:

  • Attend 4 study visits over 2 years (at 6-monthly intervals in the first year, with final assessment at end of year 2), each lasting up to 2 hours.
  • Undergo comprehensive screening assessments including mobility, cognition, mental health, hearing, vision, and nutritional status.
  • Receive 2 follow-up phone calls at 3-month and 9-month intervals to monitor progress.
  • If in the intervention group: receive personalized referrals for further care (which may include comprehensive geriatric assessment, primary care reviews, rehabilitation, or dietitian consultations) and guidance on using a mobile health monitoring application.
  • If in the wait-list control group: receive the same interventions after their 3rd study visit (12 months later).

Description

The INFINITY-ICOPE programme integrates the concepts of frailty and intrinsic capacity - a person's physical and mental abilities essential for maintaining overall health and well-being. Since intrinsic capacity represents the physiological reserves whose decline can lead to frailty, monitoring intrinsic capacity trajectories enables timely intervention to address deteriorating physical and mental capacities. The programmme employs a tiered approach to provide comprehensive geriatric assessment for frail older adults, utilizing technology-enabled tools including the SCREENii algorithmic approach for objective physical frailty assessment and the ENGAGE app to empower older individuals through self-screening, remote intrinsic capacity monitoring, and behavioural nudges.

The investigators primary aim is maintaining older adults' independence and community engagement, measured through life-space mobility. Secondary aims encompass promoting regular screening for frailty and intrinsic capacity decline, implementing early intervention strategies, enhancing quality of life, and developing a cost-effective healthcare delivery model. INFINITY-ICOPE follows the implementation research logic model to ensure rigorous and replicable research. The study comprises 4 phases:

  1. Phase 1 (Proof-of-Concept) - 12 months. This preparatory phase focuses on 3 key areas: technology readiness, care pathway development, and stakeholder readiness assessment.
    • Technology development: The SCREENii platform will be enhanced to provide automated frailty screening through grip strength and gait speed measurements. The ENGAGE app will incorporate WHO-ICOPE Step 1 screening and deliver personalized care plans adapted for local needs.
    • Care pathway development: Personalized pathways will be developed for frailty management through regional hospital networks and intrinsic capacity domain-specific interventions based on WHO-ICOPE guidelines. Community assessors will receive training in Step 1 screening and individualized care planning, with 400 older adults recruited to test feasibility and assess intrinsic capacity decline prevalence.
    • Readiness assessment: Surveys and focus group discussions will evaluate attitudes and expectations of multidisciplinary care providers (eldercare staff, community nurses, family physicians, social workers) towards INFINITY-ICOPE implementation. Additional focus groups with 30 trained community assessors will capture their screening experiences. Usability testing with 15 older adults will assess SCREENii completion times and ENGAGE app quality using the mobile app rating scale. This phase will inform resource planning for Phase 2 and refine implementation strategies based on identified barriers and enablers.
  2. Phase 2 (Proof-of-Value) - 12 months. This single-arm pre-post pilot study will evaluate INFINITY-ICOPE's potential impact by recruiting 60 older adults (aged 60 and above) from an existing mobile frailty screening platform, termed Individual Physical Performance Test for Seniors (IPPT-S). The multi-domain geriatric screening and comprehensive fitness battery will validate SCREENii plus ICOPE Step 1 for stratifying participants by frailty and intrinsic capacity decline.
  3. Phase 3 (Testing-bed) - 30 months. This study employs a pragmatic controlled design with 540 older adults across 8 eldercare and/or active ageing centres within SingHealth zones. Intervention design: The INFINITY-ICOPE programme includes integrated frailty and intrinsic capacity screening, targeted referrals based on stratification, and 6-monthly self-monitoring via ENGAGE app and SCREENii. Participants are stratified into 3 groups post-screening: (a) Frail (regardless of intrinsic capacity status); (b) Non-frail with declining intrinsic capacity; and (c) Non-frail with intact intrinsic capacity.

Targeted interventions: Frail participants (Fried score of 3 and above) receive comprehensive geriatric assessment at geriatric specialty hubs, whilst non-frail participants with intrinsic capacity decline undergo Steps 2 to 3 assessments at Community Health Posts with personalized interventions. All intervention participants receive ENGAGE app notifications including appointment reminders, lifestyle nudges, and screening prompts. Additional cognitive assessment via Cognify (30-minute automated battery) validated cognitive screening for enhanced stratification. Control group: Continues usual activities with wait-list access to INFINITYICOPE after 12-month outcomes assessment, enabling centres to scale the programme as standard care. Data collection: Comprehensive measures collected at 6-monthly intervals include socio-demographics, frailty / sarcopenia / intrinsic capacity status, medical comorbidities, functional performance, cognitive / mood assessments, quality of life, and intervention adherence, emphasizing both clinical and implementation effectiveness for sustainability evaluation. 4. Phase 4 (Scale-up) - 6 months. This phase focuses on programme evaluation and scaling preparation without recruiting new participants. Activities centre on completing Phase 3 follow-ups, comprehensive data analysis, and sustainability assessment.

Eligibility

Inclusion Criteria: (in Phases 1, 2 and 3):

  • Any Singaporean or Permanent Resident (PR) aged 60 years and above
  • Able to provide informed consent (or legally acceptable representative available)

Exclusion Criteria (in Phases 1, 2 and 3):

  • Non-Singaporeans or non-PRs under 60 years of age
  • Residents of sheltered or nursing homes

Study details
    Frailty in Older Adults
    Intrinsic Capacity
    Age-related Functional Decline
    Healthy Ageing

NCT07477561

Sengkang General Hospital

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.